Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
After finishing at $34.75 in the prior trading day, Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) closed at $33.37, down -3.97%. In other words, the price has decreased by -$3.97 from its previous closing price. On the day, 1.04 million shares were traded. RARE stock price reached its highest trading level at $34.34 during the session, while it also had its lowest trading level at $33.185.
Ratios:
Our goal is to gain a better understanding of RARE by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.74 and its Current Ratio is at 1.89. In the meantime, Its Debt-to-Equity ratio is 94.23 whereas as Long-Term Debt/Eq ratio is at 85.75.
Upgrades & Downgrades
In the most recent recommendation for this company, Wells Fargo on October 20, 2025, initiated with a Overweight rating and assigned the stock a target price of $65.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Oct 13 ’25 when Horn Howard sold 7,942 shares for $31.51 per share. The transaction valued at 250,252 led to the insider holds 98,227 shares of the business.
Huizenga Theodore Alan sold 64 shares of RARE for $1,867 on Sep 18 ’25. The SVP, Chief Accounting Officer now owns 50,242 shares after completing the transaction at $29.17 per share. On Sep 12 ’25, another insider, KARAH PARSCHAUER, who serves as the Officer of the company, bought 2,450 shares for $31.17 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RARE now has a Market Capitalization of 3219456256 and an Enterprise Value of 3658547456. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.11 while its Price-to-Book (P/B) ratio in mrq is 350.75. Its current Enterprise Value per Revenue stands at 5.802 whereas that against EBITDA is -7.192.
Stock Price History:
The Beta on a monthly basis for RARE is 0.16, which has changed by -0.2554103 over the last 52 weeks, in comparison to a change of 0.12607694 over the same period for the S&P500. Over the past 52 weeks, RARE has reached a high of $50.00, while it has fallen to a 52-week low of $25.81. The 50-Day Moving Average of the stock is 3.55%, while the 200-Day Moving Average is calculated to be -2.00%.
Shares Statistics:
The stock has traded on average 1.50M shares per day over the past 3-months and 1257370 shares per day over the last 10 days, according to various share statistics. A total of 96.27M shares are outstanding, with a floating share count of 89.76M. Insiders hold about 6.96% of the company’s shares, while institutions hold 99.09% stake in the company. Shares short for RARE as of 1763078400 were 7828953 with a Short Ratio of 5.23, compared to 1760486400 on 8692947. Therefore, it implies a Short% of Shares Outstanding of 7828953 and a Short% of Float of 8.4.
Earnings Estimates
The firm’s stock currently is rated by 12.0 analysts. The consensus estimate for the next quarter is -$1.47, with high estimates of -$0.91 and low estimates of -$1.77.
Analysts are recommending an EPS of between -$5.33 and -$6.41 for the fiscal current year, implying an average EPS of -$5.77. EPS for the following year is -$4.47, with 12.0 analysts recommending between -$2.68 and -$6.41.
Revenue Estimates
16 analysts predict $188.05M in revenue for. The current quarter. It ranges from a high estimate of $197M to a low estimate of $175.1M. As of. The current estimate, Ultragenyx Pharmaceutical Inc’s year-ago sales were $164.88MFor the next quarter, 16 analysts are estimating revenue of $172.08M. There is a high estimate of $197.47M for the next quarter, whereas the lowest estimate is $145M.
A total of 19 analysts have provided revenue estimates for RARE’s current fiscal year. The highest revenue estimate was $667.91M, while the lowest revenue estimate was $641.7M, resulting in an average revenue estimate of $655.17M. In the same quarter a year ago, actual revenue was $560.23MBased on 19 analysts’ estimates, the company’s revenue will be $795.59M in the next fiscal year. The high estimate is $886.7M and the low estimate is $675.4M.
